AAAAAA

   
Results: 1-24 |
Results: 24
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies
Authors: Somlo, G Chow, W Hamasaki, V Leong, L Margolin, K Morgan, R Sniecinski, I Frankel, P Reardon, D Longmate, J Raschko, J Shibata, S O'Donnell, M Smith, E Tetef, M Forman, S Yen, Y Molina, A Doroshow, JH
Citation: G. Somlo et al., Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies, BIOL BLOOD, 7(5), 2001, pp. 284-293
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies
Authors: Tetef, ML Synold, TW Chow, W Leong, L Margolin, K Morgan, R Raschko, J Shibata, S Somlo, G Yen, Y Groshen, S Johnson, K Lenz, HJ Gandara, D Doroshow, JH
Citation: Ml. Tetef et al., Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies, CLIN CANC R, 7(6), 2001, pp. 1569-1576
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy
Authors: Morgan, RJ Synold, T Carr, BI Doroshow, JH Womack, EP Shibata, S Somlo, G Raschko, J Leong, L McNamara, M Chow, W Tetef, M Margolin, K Akman, S Longmate, J
Citation: Rj. Morgan et al., Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy, CANC CHEMOT, 47(4), 2001, pp. 327-332
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer
Authors: Morgan, RJ Doroshow, JH Leong, L Schriber, J Shibata, S Forman, S Hamasaki, V Margolin, K Somlo, G Alvarnas, J McNamara, M Longmate, J Raschko, J Chow, W Vasilev, S McGonigle, K Yen, Y
Citation: Rj. Morgan et al., Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer, BONE MAR TR, 28(9), 2001, pp. 859-863
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome
Authors: Somlo, G Doroshow, JH Synold, T Longmate, J Reardon, D Chow, W Forman, SJ Leong, LA Margolin, KA Morgan, RJ Raschko, JW Shibata, SI Tetef, ML Yen, Y Kogut, N Schriber, J Alvarnas, J
Citation: G. Somlo et al., High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome, BR J CANC, 84(12), 2001, pp. 1591-1598
Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin
Authors: Doroshow, JH Synold, TW Somlo, G Akman, SA Gajewski, E
Citation: Jh. Doroshow et al., Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin, BLOOD, 97(9), 2001, pp. 2839-2845
Allogeneic bone marrow transplantation for BCR-ABL positive acute lymphoblastic leukemia
Authors: Snyder, DS Nademanee, AP O'Donnell, MR Parker, PM Stein, AS Margolin, K Somlo, G Molina, A Spielberger, R Kashyap, A Fung, H Vora, N Slovak, ML Niland, J Palmer, J Negrin, RS Amylon, MD Blume, KG Forman, SJ
Citation: Ds. Snyder et al., Allogeneic bone marrow transplantation for BCR-ABL positive acute lymphoblastic leukemia, HEMAT BLOOD, 40, 2001, pp. 414-418
Esthetic reconstruction after mastectomy for inflammatory breast cancer: Is it worthwhile?
Authors: Chin, PL Andersen, JS Somlo, G Chu, DZJ Schwarz, RE Ellenhorn, JDI
Citation: Pl. Chin et al., Esthetic reconstruction after mastectomy for inflammatory breast cancer: Is it worthwhile?, J AM COLL S, 190(3), 2000, pp. 304-309
NCCN Practice Guidelines for breast cancer
Authors: Carlson, RW Anderson, BO Bensinger, W Cox, CE Davidson, NE Edge, SB Farrar, WB Goldstein, LJ Gradishar, WJ Lichter, AS McCormick, B Nabell, LM Reed, EC Silver, SM Smith, ML Somlo, G Theriault, R Ward, JH Winer, EP Wolff, A
Citation: Rw. Carlson et al., NCCN Practice Guidelines for breast cancer, ONCOLOGY-NY, 14(11A), 2000, pp. 33-49
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission
Authors: Stein, AS O'Donnell, MR Slovak, ML Nademanee, A Dagis, A Schmidt, GM Parker, PM Snyder, DS Smith, EP Somlo, G Margolin, KA Arber, D Niland, J Forman, SJ
Citation: As. Stein et al., High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission, LEUKEMIA, 14(7), 2000, pp. 1191-1196
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
Authors: Ozer, H Armitage, JO Bennett, CL Crawford, J Demetri, GD Pizzo, PA Schiffer, CA Smith, TJ Somlo, G Wade, JC Wade, JL Winn, RJ Wozniak, AJ Somerfield, MR
Citation: H. Ozer et al., 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines, J CL ONCOL, 18(20), 2000, pp. 3558-3585
Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An International Oncology Study Group (IOSG) Phase II protocol
Authors: Giles, FJ Wickham, NR Rapoport, BL Somlo, G Lim, SW Shan, JQ Lynott, AM
Citation: Fj. Giles et al., Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An International Oncology Study Group (IOSG) Phase II protocol, AM J HEMAT, 63(3), 2000, pp. 125-130
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A
Authors: Raschko, JW Synold, TW Chow, W Coluzzi, P Hamasaki, V Leong, LA Margolin, KA Morgan, RJ Shibata, SI Somlo, G Tetef, ML Yen, Y ter Veer, A Doroshow, JH
Citation: Jw. Raschko et al., A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A, CANC CHEMOT, 46(5), 2000, pp. 403-410
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in thetreatment of leptomeningeal carcinomatosis
Authors: Tetef, ML Margolin, KA Doroshow, JH Akman, S Leong, LA Morgan, RJ Raschko, JW Slatkin, N Somlo, G Longmate, JA Carroll, MI Newman, EM
Citation: Ml. Tetef et al., Pharmacokinetics and toxicity of high-dose intravenous methotrexate in thetreatment of leptomeningeal carcinomatosis, CANC CHEMOT, 46(1), 2000, pp. 19-26
Transplantation of CD34(+) peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial
Authors: Yanovich, S Mitsky, P Cornetta, K Maziarz, RT Rosenfeld, C Krause, DS Lotz, JP Bitran, JD Williams, B Preti, R Somlo, G Burtness, B Mills, B
Citation: S. Yanovich et al., Transplantation of CD34(+) peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial, BONE MAR TR, 25(11), 2000, pp. 1165-1174
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up
Authors: Morgan, RJ Braly, P Leong, L Shibata, S Margolin, K Somlo, G McNamara, M Longmate, J Schinke, S Raschko, J Nagasawa, S Kogut, N Najera, L Johnson, D Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up, GYNECOL ONC, 77(3), 2000, pp. 433-438
Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer
Authors: Wong, JYC Somlo, G Odom-Maryon, T Williams, LE Liu, A Yamauchi, D Wu, AM Yazaki, P Wilczynski, S Shively, JE Forman, S Doroshow, JH Raubitschek, AA
Citation: Jyc. Wong et al., Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer, CLIN CANC R, 5(10), 1999, pp. 3224S-3231S
Program understanding behavior during corrective maintenance of large-scale software
Authors: Vans, AM von Mayrhauser, A Somlo, G
Citation: Am. Vans et al., Program understanding behavior during corrective maintenance of large-scale software, INT J HUM-C, 51(1), 1999, pp. 31-70
Beyond palliative mastectomy in inflammatory breast cancer - A reassessment of margin status
Authors: Curcio, LD Rupp, E Williams, WL Chu, DZJ Clarke, K Odom-Maryon, T Ellenhorn, JDI Somlo, G Wagman, LD
Citation: Ld. Curcio et al., Beyond palliative mastectomy in inflammatory breast cancer - A reassessment of margin status, ANN SURG O, 6(3), 1999, pp. 249-254
Update: NCCN practice guidelines for the treatment of breast cancer
Authors: Carlson, RW Anderson, BO Bensinger, W Cox, C Davidson, NE Edge, SB Farrar, WB Goldstein, LJ Gradishar, WJ Lichter, AS Mccormick, B Nabell, LM Reed, EC Silver, SM Smith, MLP Somlo, G Theriault, RL Winer, EP
Citation: Rw. Carlson et al., Update: NCCN practice guidelines for the treatment of breast cancer, ONCOLOGY-NY, 13(11A), 1999, pp. 187-212
Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission
Authors: Snyder, DS Nademanee, AP O'Donnell, MR Parker, PM Stein, AS Margolin, K Somlo, G Molina, A Spielberger, R Kashyap, A Fung, H Slovak, ML Dagis, A Negrin, RS Amylon, MD Blume, KG Forman, SJ
Citation: Ds. Snyder et al., Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission, LEUKEMIA, 13(12), 1999, pp. 2053-2058
Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial
Authors: Tetef, M Leong, L Ahn, C Akman, S Chow, W Margolin, K Morgan, RJ Raschko, J Shibata, S Somlo, G Doroshow, JH
Citation: M. Tetef et al., Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial, CANCER INV, 17(2), 1999, pp. 114-117
Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up
Authors: Morgan, RJ Braly, P Cecchi, G Leong, L Shibata, S Margolin, K Somlo, G McNamara, M Longmate, J Schinke, S Raschko, J Nagasawa, S Kogut, N Parker, P Stein, A Cho, J Smith, E Coluzzi, P Najera, L Johnson, D Womack, E Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up, GYNECOL ONC, 75(3), 1999, pp. 419-426
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy
Authors: Somlo, G Sniecinski, I ter Veer, A Longmate, J Knutson, G Vuk-Pavlovic, S Bhatia, R Chow, W Leong, L Morgan, R Margolin, K Raschko, J Shibata, S Tetef, M Yen, Y Forman, S Jones, D Ashby, M Fyfe, G Hellmann, S Doroshow, JH
Citation: G. Somlo et al., Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy, BLOOD, 93(9), 1999, pp. 2798-2806
Risultati: 1-24 |